德纳维制药(DVAX.US)暴涨超39%，最高触及15.49美元，创2022年8月以来新高。消息面上，赛诺菲宣布，同意以每股15.5美元的现金收购德纳维制药，旨在扩充其目前以流感疫苗业务为核心的疫苗产品线。该报价较达德纳维制药周二的收盘价溢价39%，交易价值约22亿美元。此项收购有望于2026年第一季度完成。(格隆汇)
德纳维制药(DVAX.US)暴涨超39%，最高触及15.49美元，创2022年8月以来新高。消息面上，赛诺菲宣布，同意以每股15.5美元的现金收购德纳维制药，旨在扩充其目前以流感疫苗业务为核心的疫苗产品线。该报价较达德纳维制药周二的收盘价溢价39%，交易价值约22亿美元。此项收购有望于2026年第一季度完成。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.